Pharmaceutical stocks, including Pfizer (NYSE: PFE), have recently been scrutinized after President Trump’s executive order instructing drug manufacturers to reduce medicine prices to align with ...

Pfizer announced last month that it was discontinuing development of its experimental weight-loss pill, danuglipron, after a trial participant experienced potential drug-induced liver injury.

Drugmakers Pfizer and Flynn Pharma have been ... so they were no longer subject to price regulations. Pfizer hiked the price of the drug between 780% and 1,600%, and also supplied the drug to ...

The agreement covers the development, manufacturing and commercialisation of the drug. Pfizer has been granted a global license, excluding China, as well as the option to obtain commercialisation ...

Ongoing tariff disputes and President Trump’s drug pricing order heighten uncertainties for AbbVie Inc. and Pfizer Inc. The more uncertain the time, the more investors should focus on return ...

Pfizer’s ongoing focus on oncology and vaccines was emphasized, with significant investments in research and development. The company is also progressing with its cost restructuring program, aiming ...

Pfizer's COVID vaccine co-developed with BioNTech, which generated $565 million and outpaced the $325.5 million estimate. Sales of flagship drug Eliquis fell 4% operationally amid ongoing pricing ...

For example, the effects of drug pricing controls introduced by ... possibly Trump's stance on rolling back IRA regulations – suggests Pfizer will surprise the market with any outperformance ...

That decline was only partly offset by Comirnaty, Pfizer's COVID vaccine co-developed with BioNTech, which generated $565 million and outpaced the $325.5 million estimate. Sales of flagship drug ...